A genetic bleeding disorder, haemophilia worsens quality of life, can cause deformities and disabilities and in the worst of ...

According to StatPearls, haemophilia is found globally at a rate of 1 in 1,25,000 individuals. The prevalence of haemophilia B is 3.8 cases per 1,00,000 live males and 5 cases per 1,00,000 males born.

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. In fact, in the 1950s and 1960s, life expectancy for the disease was around ...

Haemophilia is a genetic disorder that impairs the blood's ability to clot normally. It is caused by a deficiency in clotting factors, blood proteins that help prevent bleeding.

You must have noticed that when you get injured, your blood turns to a gel, forming a blood clot. This mess your body is healing well. However, if you have haemophilia B, your blood won’t be able to ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab) for adults and adolescents with haemophilia A or B with inhibitors. The ...

The petition was filed by Prema Ram who appeared in the Civil Services Examination conducted by the Union Public Service Commission (UPSC) in May this year ...

Haemophilia, a rare bleeding disorder, once drastically shortened lifespans. Prophylaxis, involving regular clotting factor infusions, has revolutionized treatment, preventing bleeds and improving ...

Pfizer’s Hympavzi, given as a once-weekly subcutaneous injection using a pre-filled pen, works by reducing the amount of TFPI, a naturally occurring protein that prevents blood from clotting too much.

The first patient in the UK has been treated by the NHS with CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec). The patient from the North East of England was treated at ...